Biomarkers in sepsis-looking for the Holy Grail or chasing a mirage!

Neelmani Ahuja, Anjali Mishra, Ruchi Gupta, Sumit Ray
{"title":"Biomarkers in sepsis-looking for the Holy Grail or chasing a mirage!","authors":"Neelmani Ahuja,&nbsp;Anjali Mishra,&nbsp;Ruchi Gupta,&nbsp;Sumit Ray","doi":"10.5492/wjccm.v12.i4.188","DOIUrl":null,"url":null,"abstract":"<p><p>Sepsis is defined as a life-threatening organ dysfunction caused by the dysregulated host response to infection. It is a complex syndrome and is characterized by physiologic, pathologic and biochemical abnormalities in response to an infection. Diagnosis of sepsis is based on history, physical examination and other investigations (including biomarkers) which may help to increase the certainty of diagnosis. Biomarkers have been evaluated in the past for many diseases and have been evaluated for sepsis as well. Biomarkers may find a possible role in diagnosis, prognostication, therapeutic monitoring and anti-microbial stewardship in sepsis. Since the pathophysiology of sepsis is quite complex and is incompletely understood, a single biomarker that may be robust enough to provide all information has not been found as of yet. However, many biomarkers have been studied and some of them have applications at the bedside and guide clinical decision-making. We evaluated the PubMed database to search for sepsis biomarkers for diagnosis, prognosis and possible role in antibiotic escalation and de-escalation. Clinical trials, meta-analyses, systematic reviews and randomized controlled trials were included. Commonly studied biomarkers such as procalcitonin, Soluble urokinase-type plasminogen activator (Supar), presepsin, soluble triggering receptor expressed on myeloid cells 1, interleukin 6, C-reactive protein, <i>etc</i>., have been described for their possible applications as biomarkers in septic patients. The sepsis biomarkers are still an area of active research with newer evidence adding to the knowledge base continuously. For patients presenting with sepsis, early diagnosis and prompt resuscitation and early administration of anti-microbials (preferably within 1 h) and source control are desired goals. Biomarkers may help us in the diagnosis, prognosis and therapeutic monitoring of septic patients. The marker redefining our view on sepsis is yet a mirage that clinicians and researchers continue to chase.</p>","PeriodicalId":66959,"journal":{"name":"世界危重病急救学杂志(英文版)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/8d/WJCCM-12-188.PMC10515097.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界危重病急救学杂志(英文版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5492/wjccm.v12.i4.188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Sepsis is defined as a life-threatening organ dysfunction caused by the dysregulated host response to infection. It is a complex syndrome and is characterized by physiologic, pathologic and biochemical abnormalities in response to an infection. Diagnosis of sepsis is based on history, physical examination and other investigations (including biomarkers) which may help to increase the certainty of diagnosis. Biomarkers have been evaluated in the past for many diseases and have been evaluated for sepsis as well. Biomarkers may find a possible role in diagnosis, prognostication, therapeutic monitoring and anti-microbial stewardship in sepsis. Since the pathophysiology of sepsis is quite complex and is incompletely understood, a single biomarker that may be robust enough to provide all information has not been found as of yet. However, many biomarkers have been studied and some of them have applications at the bedside and guide clinical decision-making. We evaluated the PubMed database to search for sepsis biomarkers for diagnosis, prognosis and possible role in antibiotic escalation and de-escalation. Clinical trials, meta-analyses, systematic reviews and randomized controlled trials were included. Commonly studied biomarkers such as procalcitonin, Soluble urokinase-type plasminogen activator (Supar), presepsin, soluble triggering receptor expressed on myeloid cells 1, interleukin 6, C-reactive protein, etc., have been described for their possible applications as biomarkers in septic patients. The sepsis biomarkers are still an area of active research with newer evidence adding to the knowledge base continuously. For patients presenting with sepsis, early diagnosis and prompt resuscitation and early administration of anti-microbials (preferably within 1 h) and source control are desired goals. Biomarkers may help us in the diagnosis, prognosis and therapeutic monitoring of septic patients. The marker redefining our view on sepsis is yet a mirage that clinicians and researchers continue to chase.

败血症的生物标志物寻找圣杯或追逐海市蜃楼!
脓毒症被定义为由宿主对感染反应失调引起的危及生命的器官功能障碍。它是一种复杂的综合征,以感染引起的生理、病理和生化异常为特征。败血症的诊断基于病史、体检和其他调查(包括生物标志物),这可能有助于提高诊断的确定性。生物标志物在过去已经被评估用于许多疾病,并且也被评估用于败血症。生物标志物可能在败血症的诊断、预测、治疗监测和抗微生物管理中发挥作用。由于败血症的病理生理学非常复杂,而且还不完全了解,因此到目前为止,还没有发现一种足够强大的生物标志物来提供所有信息。然而,许多生物标志物已经被研究,其中一些在床边有应用,并指导临床决策。我们评估了PubMed数据库,以搜索用于诊断、预后以及在抗生素升级和降级中可能发挥作用的败血症生物标志物。包括临床试验、荟萃分析、系统综述和随机对照试验。通常研究的生物标志物,如降钙素原、可溶性尿激酶型纤溶酶原激活剂(Supar)、前蛋白酶、髓细胞上表达的可溶性触发受体1、白细胞介素6、C反应蛋白等,已被描述为可能在脓毒症患者中用作生物标志物。败血症生物标志物仍然是一个活跃的研究领域,新的证据不断添加到知识库中。对于败血症患者,早期诊断和及时复苏以及早期给予抗微生物药物(最好在1小时内)和源头控制是理想的目标。生物标志物可能有助于我们对败血症患者的诊断、预后和治疗监测。重新定义我们对败血症看法的标志物仍然是临床医生和研究人员继续追逐的海市蜃楼。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
216
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信